OBCK logo

Ottobock SE & Co. KGaA Stock Price

XTRA:OBCK Community·€3.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

OBCK Share Price Performance

€54.05
-14.95 (-21.67%)
€87.50
Fair Value
€54.05
-14.95 (-21.67%)
38.2% undervalued intrinsic discount
€87.50
Fair Value
Price €54.05
AnalystConsensusTarget €87.50

OBCK Community Narratives

AnalystConsensusTarget·
Fair Value €87.5 38.2% undervalued intrinsic discount

Neuro Rehabilitation Demand And Reimbursement Expansion Will Drive Long-Term Mobility Solutions Upside

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
€87.5
38.2% undervalued intrinsic discount
Revenue
6.88% p.a.
Profit Margin
12.88%
Future PE
31.73x
Price in 2028
€104.53

Trending Discussion

Updated Narratives

OBCK logo

Neuro Rehabilitation Demand And Reimbursement Expansion Will Drive Long-Term Mobility Solutions Upside

Fair Value: €87.5 38.2% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with solid track record.

1 Risk
4 Rewards

Ottobock SE & Co. KGaA Key Details

€1.7b

Revenue

€793.3m

Cost of Revenue

€886.5m

Gross Profit

€796.3m

Other Expenses

€90.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 06, 2026
1.41
52.77%
5.37%
230.5%
View Full Analysis

About OBCK

Founded
1919
Employees
9486
CEO
Oliver Jakobi
WebsiteView website
corporate.ottobock.com/en/home

Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. The company is involved in identification, development, manufacturing, sales, and marketing of prosthetics, neuro-orthotics, and digital solutions; prostheses for the upper and lower extremities; mechanical prostheses and technologically sophisticated microprocessor-controlled; prosthetic knee joints and feet; arm and hand prostheses; and myoelectrical prostheses activities, as well as socket technologies, including liners, intelligent adaptors, and cosmetic components. It also provides fitting solutions for neurological indications; microprocessor-controlled orthotics, such as the C-Brace; and electrical muscle-activating stimulators, including exopulse suit and conventional orthotics; planning and equipping of patient care clinics; solutions for back, shoulder, neck, and wrist; customized orthopedic treatment and rehabilitation solutions; manual and power wheel chair; and standing aids and cushions, as well as care for amputees, including peripheral artery disease, traumatic limb loss, cancer, infections, congenital limb deficiencies, etc; and neurological etiologies, including stroke, multiple sclerosis, cerebral palsy/spinal cord injury, etc. In addition, the company leases out products, including wheelchairs and microprocessor-controlled knee joints. Ottobock SE & Co. was formerly known as Otto Bock HealthCare GmbH and changed its name to Ottobock SE & Co. KGaA in April 2018. The company was founded in 1919 and is based in Duderstadt, Germany. Ottobock SE & Co. KGaA operates as a subsidiary of Näder Upside 2 Vermögensverwaltungs GmbH.

Recent OBCK News & Updates

Recent updates

No updates